Literature DB >> 8970377

Activated neutrophils secrete stored alpha 1-antitrypsin.

P Pääkkö1, M Kirby, R M du Bois, A Gillissen, V J Ferrans, R G Crystal.   

Abstract

Neutrophil elastase (NE), a potent serine protease, is stored in primary granules of neutrophils and released following neutrophil activation. Alpha-1-antitrypsin (alpha 1-AT), the major inhibitor of NE, is synthesized by mature neutrophils. In the context of the maintenance of tissue homeostasis, we hypothesized that neutrophils may be able to store alpha 1-AT, thus having it available for release concordantly with NE. Immunofluorescence and quantitative flow-cytometric studies of neutrophils and monocytes labeled with fluorescein-conjugated alpha 1-AT-antibody demonstrated larger amounts of cytoplasmic alpha 1-AT in neutrophils than in monocytes. [35S]methionine-labeling and anti-alpha 1-AT immunoprecipitation analysis showed that although both neutrophils and monocytes synthesize alpha 1-AT, the proportion of newly synthesized intracellular alpha 1-AT was much higher in neutrophils than in monocytes. Flow-cytometric analysis showed that in the presence of surface stimulation with cytochalasin B followed by formyl-methionyleucylphenylalanine (fMLP), mean intracellular alpha 1-AT was decreased in stimulated neutrophils compared with that in resting cells, suggesting that the stored alpha 1-AT was rapidly released following surface triggering. Evaluation of surface-stimulated neutrophils by [35S]methionine labeling and anti-alpha 1-AT immunoprecipitation demonstrated increased secretion of alpha 1-AT compared with that of resting neutrophils, with some of the secreted alpha 1-AT capable of forming complexes with NE. Thus, neutrophils respond to surface stimulation not only by secreting NE but also by secreting its inhibitor, alpha 1-AT, suggesting that these cells have an inherent mechanism for damping the local effects of NE, their most powerful proteolytic enzyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970377     DOI: 10.1164/ajrccm.154.6.8970377

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

Review 1.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

2.  α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8.

Authors:  David A Bergin; Emer P Reeves; Paula Meleady; Michael Henry; Oliver J McElvaney; Tomás P Carroll; Claire Condron; Sanjay H Chotirmall; Martin Clynes; Shane J O'Neill; Noel G McElvaney
Journal:  J Clin Invest       Date:  2010-11-08       Impact factor: 14.808

3.  Accelerated Wound Border Closure Using a Microemulsion Containing Non-Inhibitory Recombinant α1-Antitrypsin.

Authors:  Alon Gimmon; Lior Sherker; Lena Kojukarov; Melodie Zaknoun; Yotam Lior; Tova Fadel; Ronen Schuster; Eli C Lewis; Eldad Silberstein
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

4.  Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity.

Authors:  M Gziut; H J MacGregor; T G Nevell; T Mason; D Laight; J K Shute
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 5.  Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy.

Authors:  Joanna Wozniak; Tomasz Wandtke; Piotr Kopinski; Joanna Chorostowska-Wynimko
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

6.  Changes of Alpha1-Antitrypsin Levels in Allergen-induced Nasal Inflammation.

Authors:  Seung-Youp Shin; Gil Soon Choi; Kun Hee Lee; Sung Wan Kim; Kyu Yeoun Won; Ju Hie Lee; Joong Saeng Cho; Hae Sim Park
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-03-17       Impact factor: 3.372

Review 7.  Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Authors:  Jennifer A Dickens; David A Lomas
Journal:  Drug Des Devel Ther       Date:  2011-08-17       Impact factor: 4.162

8.  alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro.

Authors:  Inga Zelvyte; Tim Stevens; Ulla Westin; Sabina Janciauskiene
Journal:  Cancer Cell Int       Date:  2004-11-21       Impact factor: 5.722

9.  Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody.

Authors:  Lu Tan; Juan Perez; Marianna Mela; Elena Miranda; Keith A Burling; Farshid N Rouhani; Dawn L DeMeo; Imran Haq; James A Irving; Adriana Ordóñez; Jennifer A Dickens; Mark Brantly; Stefan J Marciniak; Graeme J M Alexander; Bibek Gooptu; David A Lomas
Journal:  Int J Biochem Cell Biol       Date:  2014-11-13       Impact factor: 5.085

Review 10.  The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions.

Authors:  Sabina Janciauskiene; Sabine Wrenger; Stephan Immenschuh; Beata Olejnicka; Timm Greulich; Tobias Welte; Joanna Chorostowska-Wynimko
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.